Literature DB >> 19249470

Circulating adhesion molecules and purine nucleotides during kidney allograft reperfusion.

L Domanski1, A Pawlik, K Safranow, M Gryczman, T Sulikowski, K Jakubowska, M Olszewska, V Dziedziejko, M Ostrowski, D Chlubek, K Ciechanowski.   

Abstract

The impairment of organ function due to ischemia-reperfusion injury is still an important problem in solid organ transplantation. Numerous experimental and clinical studies of native organs have shown that ischemia-reperfusion constitutes an acute inflammatory process involving cell surface adhesion molecule expression. These markers are crucial for the recruitment and infiltration of effector cells into the postischemic tissue. Purines released by the postischemic tissue as the products of the degradation of high-energy nucleotides can be regarded as markers of disturbed energy metabolism. The aim of this study was to examine the correlation between circulating adhesion molecules and purine metabolites in graft renal vein plasma during 49 cases of kidney reperfusion. E-selectin, ICAM-1, and VCAM-1 concentrations correlated positively with hypoxanthine concentrations during reperfusion, whereas the concentrations of ICAM-1 correlated negatively with xanthine concentrations. The results of the present study suggested that the concentrations of adhesion molecules in the renal vein during reperfusion correlated with purine metabolites, reflecting metabolic changes in renal tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249470     DOI: 10.1016/j.transproceed.2008.08.152

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  An enhanced level of VCAM in transplant preservation fluid is an independent predictor of early kidney allograft dysfunction.

Authors:  Michael Baboudjian; Bastien Gondran-Tellier; Romain Boissier; Patricia Ancel; Juline Marjollet; Luc Lyonnet; Pauline François; Florence Sabatier; Eric Lechevallier; Anne Dutour; Pascale Paul
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.